|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Pfizer_Inc.
|
|
gptkbp:acquired
|
gptkb:Pfizer
|
|
gptkbp:acquisition
|
gptkb:2019
subsidiary of Pfizer
|
|
gptkbp:business_model
|
research and development
|
|
gptkbp:ceo
|
gptkb:Michael_A._Mc_Garrity
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
published
|
|
gptkbp:collaborations
|
academic institutions
biopharmaceutical companies
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:employees
|
approximately 300
|
|
gptkbp:financial_performance
|
publicly traded
|
|
gptkbp:focus
|
cancer therapeutics
|
|
gptkbp:founded
|
gptkb:1998
|
|
gptkbp:founder
|
gptkb:Ron_Cohen
|
|
gptkbp:headquarters
|
gptkb:Boulder,_Colorado
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Array Bio Pharma
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
numerous
|
|
gptkbp:investment
|
various venture capital firms
R& D focused
|
|
gptkbp:language_of_instruction
|
multiple drug candidates
|
|
gptkbp:leadership
|
experienced management team
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
global
|
|
gptkbp:marketing_strategy
|
partnerships and collaborations
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:products
|
gptkb:Braftovi
Mektovi
Binimetinib
Encorafenib
small molecule drugs
|
|
gptkbp:publishes
|
numerous
|
|
gptkbp:regulatory_compliance
|
FDA approved
|
|
gptkbp:research_areas
|
oncology
immuno-oncology
targeted therapy
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
targeted therapies
other solid tumors
|
|
gptkbp:social_responsibility
|
committed
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.arraybiopharma.com
|